



# DURECT Corporation Presenting at The UBS Warburg Global Life Sciences Conference

CUPERTINO, Calif., Oct 4, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Warburg Global Life Sciences Conference. The conference is being held at The Plaza Hotel in New York City. Thomas A. Schreck, Chief Financial Officer, will be presenting at the conference on Monday, October 7, 2002 at 3:00 p.m. EDT.

A live audio webcast of Mr. Schreck's presentation will be available by accessing UBS Warburg's homepage at <http://www.ubswarburg.com> and clicking on UBS Warburg Conferences in the lower right hand corner. Follow the link for the webcast under the Global Life Sciences Conference heading.

DURECT Corporation ([www.durect.com](http://www.durect.com)) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. In November 2001, DURECT completed a pilot phase III program for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System, a 3-month product for the treatment of chronic pain. DURECT owns three proprietary drug delivery platform technologies, including the SABER(TM) Delivery System (a patented and versatile depot injectable useful for protein delivery), the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system) and the DURIN(TM) Biodegradable Implant (drug-loaded implant system).

NOTE: CHRONOGESIC(TM) is a trademark of DURECT Corporation. SABER(TM), MICRODUR(TM) and DURIN(TM) are trademarks of Southern BioSystems, Inc., a wholly owned subsidiary of DURECT Corporation. Other trademarks referred to belong to their respective owners.

The statements in this press release regarding DURECT's products in development and product development plans, are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, DURECT's ability to research, develop, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies, manage its growth and expenses, finance its activities and operations, as well as marketplace acceptance of DURECT's products. Further information regarding these and other risks is included in DURECT's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 filed with the SEC on March 28, 2002, under the heading "Factors that may affect future results," and other periodic reports filed with the SEC. CHRONOGESIC is under development by DURECT and has not been submitted or approved for commercialization by the US Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation

CONTACT:

Schond L. Greenway, Senior Director, Investor Relations and Strategic Planning of DURECT Corporation, +1-408-777-1417, or



[schond.greenway@durect.com](mailto:schond.greenway@durect.com)

/Photo: NewsCom: <http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO>

AP Archive: <http://photoarchive.ap.org>

PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840

URL:

<http://www.ubswarburg.com>

<http://www.durect.com>

Copyright (C) 2002 PR Newswire. All rights reserved.